Clinical Trial Update: A Study to Evaluate Luspatercept Treatment Patterns and Outcomes in Erythropoiesis-Stimulating Agents-Naïve Patients With Lower-Risk Myelodysplastic Syndromes in the United States

View source ↗

Summary

The completed study, sponsored by Bristol-Myers Squibb, evaluates luspatercept treatment patterns and outcomes in ESA-naïve patients with lower-risk myelodyspla…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Luspatercept (luspatercept)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Myelodysplastic Syndromes | Status: COMPLETED